Skip to main content
. Author manuscript; available in PMC: 2013 Sep 6.
Published in final edited form as: Neuroscience. 2012 May 18;219:33–47. doi: 10.1016/j.neuroscience.2012.05.003

Figure 3.

Figure 3

Rapamycin does not change seizure susceptibility to kainate. Rats were treated with vehicle or rapamycin for three days prior to induction of seizures by kainate (labeled as KA and Rap/KA, respectively) at 10 mg/kg (A–C). Behavioral seizures are presented as average seizure duration (min) (kainate: 5.26 ± 0.51 vs rapamycin/kainate: 5.13 ± 1.48) (A), average seizure scale (kainate: 1.39 ± 0.21 vs rapamycin/kainate: 1.46 ± 0.39) (B), and average number of stage 4 and 5 seizures (kainate: 0.88 ± 0.23 vs rapamycin/kainate: 1.0 ± 0.27) (C). (mean ± SEM; n=9–10). Typical electrographic seizures recorded from cortex in immature rats that were treated with kainate at 20 mg/kg (D) or rapamycin plus kainate at 20 mg/kg (E). Quantification of electrographic seizures presented as total seizure duration (min) (kainate: 17.165± 2.098 vs rapamycin/kainate: 14.217 ± 1.502) (F), average of total SE duration (min) (kainate: 8.315 ± 2.177 vs rapamycin/kainate: 8.074 ± 2.446) (G), and latency to onset of seizures (min) (kainate: 13.15 ± 0.998 vs rapamycin/kainate: 13.330 ± 1.717) (H). (mean ± SEM; n=9).